Arthur Kirsch Purchases 10,000 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) Director Arthur Kirsch bought 10,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were bought at an average price of $13.30 per share, for a total transaction of $133,000.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $133,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Evommune Stock Performance

NYSE:EVMN opened at $13.53 on Friday. The business’s fifty day moving average is $20.58 and its 200 day moving average is $22.07. The firm has a market cap of $487.35 million and a price-to-earnings ratio of -1.42. Evommune, Inc. has a 52-week low of $12.07 and a 52-week high of $33.20.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Equities analysts predict that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EVMN. Weiss Ratings lowered shares of Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Oppenheimer initiated coverage on shares of Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target for the company. Wall Street Zen cut shares of Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Raymond James Financial downgraded Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price objective on shares of Evommune in a research note on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EVMN. Capricorn Fund Managers Ltd bought a new position in Evommune in the fourth quarter valued at $1,027,000. China Universal Asset Management Co. Ltd. bought a new stake in Evommune during the fourth quarter worth about $34,000. Sectoral Asset Management Inc. purchased a new position in shares of Evommune in the 4th quarter worth about $10,084,000. Geode Capital Management LLC purchased a new position in shares of Evommune in the 4th quarter worth about $1,881,000. Finally, Seven Grand Managers LLC bought a new position in shares of Evommune during the 4th quarter valued at about $1,284,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.